Navigation Links
Isis Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
Date:9/4/2013

CARLSBAD, Calif., Sept. 4, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 2:05 p.m. ET in New York, NY.

(Logo:  http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 29 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.  In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013
2. Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
4. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
5. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
6. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
7. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
8. AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
9. Alexza Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
10. Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
11. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 To mark the ... , Inc., a leader in digital imaging solutions, will ... East convention, held at New York,s ... Save Your Vision Month, sponsored by the American Optometric Association, ... the importance of receiving comprehensive eye exams. In recognition of ...
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales forecasts ... is legal will generate $655 million in taxes on retail sales. ... taxes, such as Washington State,s 37% cannabis ... state sales taxes that are applied on all retail sales. By ...
(Date:3/27/2017)... 2017   Pulmatrix, Inc . (NASDAQ: PULM), a clinical ... pulmonary diseases, today announced that it has added two experts ... asthma to its Scientific Advisory Board . ... B. Moss , MD, former chief of the Pediatric Pulmonary ... Center at Stanford University, and David ...
Breaking Medicine Technology:
(Date:3/27/2017)... IL (PRWEB) , ... March 27, 2017 , ... ... systems, recently received the CE Certificate of Conformity for the Smart System® 20/20. ... or exceed the highest industry standards and specifications such as ANSI, ISO and ...
(Date:3/27/2017)... ... March 27, 2017 , ... Advantexe ... announced the launch of a new research study, The Business Readiness Report. The ... execute that strategy, and the actual success of achieving individual and company goals. ...
(Date:3/27/2017)... ... 2017 , ... According to the American Cancer Society , the average ... 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, the ... avoid this latter group, tune in to Lifestyle Magazine on April 9, ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year ... be an opportunity for area-residents to celebrate two great years while also familiarizing ...
(Date:3/25/2017)... ... , ... Getting earned media coverage meaningful for Garden Media Group's clients is ... year, Garden Media aims to provide material helpful to clients’ goals and bottom lines. ... key messages to gain coveted media placements, Garden Media wows clients year-round. , ...
Breaking Medicine News(10 mins):